A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

This study is testing whether a new drug combination — BL-B01D1 (an antibody-drug conjugate) combined with lenvatinib (a targeted therapy) — is safe and effective for people with advanced liver cancer (hepatocellular carcinoma, or HCC) that has spread or cannot be surgically removed. **You may be eligible if...** - You are 18–75 years old - You have advanced liver cancer confirmed by tissue biopsy or imaging - You have at least one measurable tumor - Your ECOG performance score is 0 or 1 (meaning you are generally functional and active) - Your heart, liver, kidney, and blood counts meet the study's minimum requirements - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have severe heart problems or a heart ejection fraction below 50% - You have unresolved serious side effects from prior cancer treatments - You are outside the 18–75 age range - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.